The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI

被引:32
作者
Kostic, Jelena [1 ]
Djordjevic-Dikic, Ana [1 ,2 ]
Dobric, Milan [1 ,2 ]
Milasinovic, Dejan [1 ]
Nedeljkovic, Milan [1 ,2 ]
Stojkovic, Sinisa [1 ,2 ]
Stepanovic, Jelena [1 ,2 ]
Tesic, Milorad [1 ]
Trifunovic, Zoran [3 ,4 ]
Zamaklar-Tifunovic, Danijela [1 ,2 ]
Radosavljevic-Radovanovic, Mina [1 ,2 ]
Ostojic, Miodrag [2 ]
Beleslin, Branko [1 ,2 ]
机构
[1] Clin Ctr Serbia, Clin Cardiol, Belgrade, Serbia
[2] Univ Belgrade, Belgrade, Serbia
[3] Mil Med Acad, Belgrade 11002, Serbia
[4] Univ Def, Fac Med, Belgrade, Serbia
关键词
STEMI; Primary PCI; Nicorandil; Microvascular dysfunction; Index of microvascular resistance; Transthoracic Doppler derived coronary flow reserve; PERCUTANEOUS CORONARY INTERVENTION; INTRACORONARY ADENOSINE; INTRAVENOUS NICORANDIL; TRANSTHORACIC DOPPLER; MICROCIRCULATORY RESISTANCE; NO-REFLOW; REPERFUSION; FLOW; OUTCOMES; THERAPY;
D O I
10.1186/s12947-015-0020-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Nicorandil, as a selective potassium channel opener, has dual action including coronary and peripheral vasodilatation and cardioprotective effect through ischemic preconditioning. Considering those characteristics, nicorandil was suggested to reduce the degree of microvascular dysfunction. Methods: Thirty-two patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (pPCI) were included in the study. Index of microvascular resistance (IMR) was measured in all patients immediatelly after pPCI before the after administration of Nicorandil. ST segment resolution was monitored before intervention and 60 min after terminating the procedure. Echocardiographic evaluation of myocardial function and transthoracic Doppler derived Coronary flow reserve (CFR) of infarct related artery (IRA) was performed during hospitalization and 3 months later. Results: IMR was significantly lower after administration of Nicorandil (9.9 +/- 3.7 vs. 14.1 +/- 5.1, p < 0.001). There was significant difference in ST segment elevation before and after primary PCI with administration of Nicorandil (6.9 +/- 3.7 mm vs. 1.6 +/- 1.6 mm, p < 0.001). Transthoracic Doppler CFR measurement improved after 3 months (2.69 +/- 0.38 vs. 2.92 +/- 0.54, p = 0.021), as well as WMSI (1.14 +/- 0.17 vs. 1.07 +/- 0.09, p = 0.004). Conclusion: Intracoronary Nicorandil administration after primary PCI significantly decreases IMR, resulting in improved CFR and ventricular function in patients with STEMI undergoing primary PCI.
引用
收藏
页数:8
相关论文
共 37 条
  • [11] Prognostic Value of the Index of Microcirculatory Resistance Measured After Primary Percutaneous Coronary Intervention
    Fearon, William F.
    Low, Adrian F.
    Yong, Andy S.
    McGeoch, Ross
    Berry, Colin
    Shah, Maulik G.
    Ho, Michael Y.
    Kim, Hyun-Sook
    Loh, Joshua P.
    Oldroyd, Keith G.
    [J]. CIRCULATION, 2013, 127 (24) : 2436 - 2441
  • [12] Estimation of infarct size using transthoracic Doppler echocardiographic measurement of coronary flow reserve in infarct related and reference coronary artery
    Giga, Vojislav
    Dobric, Milan
    Beleslin, Branko
    Sobic-Saranovic, Dragana
    Tesic, Milorad
    Djordjevic-Dikic, Ana
    Stepanovic, Jelena
    Nedeljkovic, Ivana
    Artiko, Vera
    Obradovic, Vladimir
    Seferovic, Petar M.
    Ostojic, Miodrag
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (01) : 169 - 175
  • [13] ATP-sensitive potassium channels: A review of their cardioprotective pharmacology
    Grover, GJ
    Garlid, KD
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2000, 32 (04) : 677 - 695
  • [14] Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade
    Henriques, JPS
    Zijlstra, F
    van 't Hof, AWJ
    de Boer, MJ
    Dambrink, JHE
    Gosselink, M
    Hoorntje, JCA
    Suryapranata, H
    [J]. CIRCULATION, 2003, 107 (16) : 2115 - 2119
  • [15] Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study
    Hirohata, Atsushi
    Yamamoto, Keizo
    Hirose, Eiki
    Kobayashi, Yuhei
    Takafuji, Hiroya
    Sano, Fumihiko
    Matsumoto, Kensuke
    Ohara, Minako
    Yoshioka, Ryo
    Takinami, Hiroyuki
    Ohe, Tohru
    [J]. EUROINTERVENTION, 2014, 9 (09) : 50 - 56
  • [16] Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure
    Iida, Satofumi
    Kinoshita, Haruki
    Holford, Nicholas H. G.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (03) : 352 - 365
  • [17] Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction
    Ishii, H
    Ichimiya, S
    Kanashiro, M
    Amano, T
    Imai, K
    Murohara, T
    Matsubara, T
    [J]. CIRCULATION, 2005, 112 (09) : 1284 - 1288
  • [18] Effects of intravenous nicorandil before reperfusion for acute myocardial infarction in patients with stress hyperglycemia
    Ishii, H
    Amano, T
    Ichimiya, S
    Matsubara, T
    Kanashiro, M
    Murohara, T
    [J]. DIABETES CARE, 2006, 29 (02) : 202 - 206
  • [19] Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction
    Ito, H
    Taniyama, Y
    Iwakura, K
    Nishikawa, N
    Masuyama, T
    Kuzuya, T
    Hori, M
    Higashino, Y
    Fujii, K
    Minamino, T
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (03) : 654 - 660
  • [20] Beneficial Effects of Intracoronary Nicorandil on Microvascular Dysfunction After Primary Percutaneous Coronary Intervention: Demonstration of Its Superiority to Nitroglycerin in a Cross-Over Study
    Ito, Noritoshi
    Nanto, Shinsuke
    Doi, Yasuji
    Kurozumi, Yuma
    Natsukawa, Tomoaki
    Shibata, Hiroyuki
    Morita, Masaya
    Kawata, Atsushi
    Tsuruoka, Ayumu
    Sawano, Hirotaka
    Okada, Ken-ichiro
    Sakata, Yasuhiko
    Kai, Tatsuro
    Hayashi, Toru
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2013, 27 (04) : 279 - 287